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Summary  Type  2  diabetes  mellitus  is  one  of  the  most  common  chronic  conditions  and  its
prevalence  has  increased  continuously  over  the  past  decades,  primarily  due  to  the  obesity
epidemic. Atrial  ﬁbrillation  (AF)  is  the  most  frequent  sustained  cardiac  arrhythmia  in  clinical
practice and  is  associated  with  increased  cardiovascular  and  cerebrovascular  morbidity  and
mortality.  Recent  studies  have  shown  that  patients  with  diabetes  have  an  increased  risk  of
AF. However,  the  results  about  the  relationship  between  diabetes  and  AF  are  still  conﬂicting.
Mechanisms  that  are  responsible  for  an  association  between  diabetes  and  AF,  as  well  as  the
adequate treatment  of  AF  in  patients  with  diabetes,  are  still  insufﬁciently  studied.  The  aim
of this  review  is  to  summarize  the  current  knowledge  of  mechanisms  that  connect  AF  and
diabetes,  the  clinical  studies  that  include  patients  with  both  conditions,  and  the  treatment
options in  modern  pharmacology.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin II receptor blocker; CI, conﬁdence
interval; HOMA, homeostatic model assessment; RAAS, renin-angiotensin-aldosterone system.
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Résumé  Le  diabète  de  type  II  est  une  des  affections  chroniques  les  plus  fréquentes  et  sa  pré-
valence a  augmenté  de  fac¸on  régulière  au  cours  des  dernières  décennies,  essentiellement  du
fait de  l’épidémie  d’obésité.  La  ﬁbrillation  atriale  est  l’arythmie  cardiaque  la  plus  fréquente  en
pratique clinique  et  est  associée  avec  une  augmentation  de  la  morbi-mortalité  cardiovasculaire
et cérébrovasculaire.  Des  études  récentes  ont  montré  que  les  patients  diabétiques  avaient
un risque  accru  de  ﬁbrillation  atriale.  Cependant,  ces  résultats  établissant  la  relation  entre
diabète et  ﬁbrillation  atriale  sont  controversés.  Les  mécanismes  responsables  d’une  telle  asso-
ciation, ainsi  que  le  traitement  de  la  ﬁbrillation  atriale  chez  les  diabétiques  sont  insufﬁsamment
étudiés à  ce  jour.  L’objectif  de  cette  revue  générale  est  de  résumer  les  données  actuelles  des
mécanismes  liant  la  ﬁbrillation  atriale  au  diabète,  ainsi  que  les  études  cliniques  qui  incluent
les patients  ayant  un  diabète  et  une  ﬁbrillation  atriale  ;  les  options  thérapeutiques  et  l’apport
de la  pharmacologie  moderne  sont  également  discutés.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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ype  2  diabetes  mellitus  is  one  of  the  most  common  chronic
onditions  and  its  prevalence  is  increasing.  In  2014,  the  num-
er  of  patients  with  diabetes  was  estimated  at  387  millions
eople  worldwide,  of  whom  around  half  were  undiagnosed
1].  The  projection  for  2035  is  that  the  number  of  patients
ith  diabetes  will  have  risen  to  592  millions  [1].  It  is  well
nown  that  cardiovascular  and  cerebrovascular  diseases  are
ubstantially  more  frequent  among  patients  with  diabetes
2].  However,  the  mechanisms  of  this  inﬂuence  are  still  not
ompletely  understood.  It  is  not  known  whether  permanent
yperglycaemia  or  wide  ﬂuctuations  in  glucose  levels—from
ypoglycaemia  to  hyperglycaemia,  which  is  commonly  seen
n  diabetes  subjects,  especially  the  treated  ones—is  most
esponsible  for  cardiovascular  damage.
Atrial  ﬁbrillation  (AF),  the  most  frequent  sustained  car-
iac  arrhythmia,  is  associated  with  an  increased  risk  of
troke,  thromboembolism,  heart  failure  and  recurrent  hos-
ital  admissions  [3].  The  prevalence  of  AF  is  constantly
ncreasing,  and  it  affects  about  2.2  million  individuals  in
merica  and  4.5  millions  in  Europe  [4,5].
Studies  have  shown  that  diabetes  is  frequently  associated
ith  AF  [6].  However,  it  is  difﬁcult  to  determine  whether
iabetes  directly  affects  the  atrial  tissue  or  whether  differ-
nt  pathways  are  involved,  including  hypertension,  coronary
rtery  disease  and  abnormal  activity  of  the  autonomic  ner-
ous  system.  The  aim  of  this  review  is  to  summarize  current
nowledge  of  the  relationships  between  diabetes  and  AF,
rom  mechanisms  to  clinically  relevant  studies.
echanisms of the relationship between
iabetes  and AF
iabetes  is  associated  with  numerous  metabolic  defects
ncluding  insulin  resistance,  impaired  glucose  tolerance,
roinﬂammatory  mediators,  abnormalities  of  haemostasis,
brinolysis,  angiogenesis  and  extracellular  matrix  turnover
7—9]  (Fig.  1).  All  of  these  metabolic  changes  lead  to
ndothelial  dysfunction,  abnormal  activation  of  the  renin-
ngiotensin-aldosterone  system  (RAAS)  and  acceleration  of
therogenesis,  which  could  be  responsible  for  AF  occurrence
v
a
a
t2,7—9].  Diabetes  could  also  cause  structural,  electrical,
lectromechanical  and  autonomic  remodelling  [10].
trial structural remodelling
ost  evidence  obtained  from  animal  studies  has  demon-
trated  that  structural  remodelling  of  the  left  atrium,
rimarily  atrial  dilatation  and  interstitial  ﬁbrosis  is  the
ajor  trigger  of  AF  in  patients  with  diabetes  [11,12].  Struc-
ural  remodelling  leads  to  ionic  remodelling  and  increases
trial  tissue  vulnerability,  which  induces  inter-atrial  conduc-
ion  delay  and,  subsequently,  initiation  and  maintenance  of
F  [11,12].
Atrial  ﬁbrosis  could  be  caused  by  inﬂammation  (oxida-
ive  stress),  increased  production  of  advanced  glycation
nd  products,  increased  expression  of  transforming  growth
actor-  and  expression  changes  of  gap  junction  proteins
10].
trial electrical remodelling
he  principal  characters  of  atrial  electrical  remodelling
nvolve  atrial  effective  refractory  period  shortening  and  its
ispersion,  as  well  as  impairment  of  its  frequency  adaptation
nd  consequent  inter-atrial  conduction  delay  [10].  Changes
n  left  atrial  diameter,  atrial  activation  time  and  voltage
n  patients  with  diabetes  have  been  associated  with  atrial
tructural  remodelling,  not  only  electrical,  especially  in
atients  with  AF.  Chao  et  al.,  for  example,  studied  patients
ith  abnormal  glucose  metabolism  (diabetes  and  impaired
lucose  tolerance)  who  underwent  radiofrequency  ablation
f  paroxysmal  AF  for  the  ﬁrst  time,  and  revealed  that  right
nd  left  atria  voltages  in  these  patients  were  signiﬁcantly
ecreased  due  to  atrial  electrical  remodelling  and  atrial
brosis  [13].
trial electromechanical remodelling
indings  from  our  group  show  that  left  and  right  atrial  reser-
oir  and  conduit  function,  assessed  by  emptying  fractions
nd  strain,  are  decreased  among  subjects  with  prediabetes
nd  patients  with  diabetes  compared  with  controls  [14].  On
he  other  hand,  left  and  right  atrial  pump  function  increased
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iFigure 1. Possible mechanisms that link diabetes and atrial ﬁbril
in  the  same  direction.  These  results  agree  with  previous
studies  [15,16].  Furthermore,  Ayhan  et  al.  found  similar
results  regarding  left  atrial  function,  and  also  revealed  that
inter-  and  intra-atrial  electromechanical  delays  were  signif-
icantly  higher  in  patients  with  glucose  intolerance  than  in
controls  [17].  Studies  have  also  shown  that  that  inter-  and
intra-atrial  electromechanical  abnormalities  are  associated
with  fasting  glucose  level  and  AF  occurrence  in  patients  with
diabetes  [11,12].
Atrial autonomic remodelling
The  inﬂuence  of  diabetes  on  the  autonomic  nervous
system—sympathetic  and  parasympathetic—is  well  known
[18,19].  Studies  have  demonstrated  that  atrial  tissue  in
patients  with  diabetes  has  a  greater  ability  to  uptake  choline
and  release  acetylcholine  [20].
Otake  et  al.  revealed  that  diabetic  mice  were  more  sus-
ceptible  to  AF  development  after  sympathetic  stimulation
than  were  controls  [21].  The  electrophysiological  investi-
gation  demonstrated  shortened  atrial  effective  refractory
period  and  increased  dispersion.  However,  parasympathetic
stimulation  in  diabetic  mice  did  not  affect  the  atrial
effective  refractory  period  or  the  occurrence  of  AF  [21].
These  ﬁndings  imply  that  neural  remodelling  could  have  an
essential  role  in  the  development  of  AF  in  patients  with
diabetes.
Clinical studies about diabetes and AF
Clinical  investigations  do  not  completely  agree  about  the
inﬂuence  of  diabetes  on  AF  occurrence.  Actually,  the  ﬁnd-
ings  of  these  studies  are  conﬂicting  (Table  1).  Some  authors
found  that  diabetes  increased  the  risk  of  AF  occurrence
[6,22,23],  whereas  other  studies  did  not  reveal  statistically
signiﬁcant  differences  in  the  risk  of  AF  development  with
diabetes  [24,25].  Interestingly,  some  authors  investigated
differences  in  AF  occurrence  between  men  and  women  with
diabetes.  Frost  et  al.  did  not  ﬁnd  any  difference  in  AF  preva-
lence  between  men  and  women  with  diabetes  [26],  whereas
d
t
i occurrence. RAAS: renin-angiotensin-aldosterone system.
enjamin  et  al.  [3]  and  Nichols  et  al.  [27]  revealed  that  DM
ncreases  the  risk  of  AF  to  a  greater  extent  in  women  than  in
en  [3,27].  A  recently  published  study  showed  that  a  signif-
cant  relationship  between  baseline  diabetes  and  incident
F  was  the  consequence  of  changes  of  other  AF  risk  factors
age,  hypertension,  obesity)  [28].
In  a Swedish  community-based  study,  the  authors  demon-
trated  that  patients  with  arterial  hypertension  and  diabetes
ad  a  threefold  higher  risk  of  AF  occurrence  compared  with
ormotensive  and  non-diabetic  control  subjects  [29].  How-
ver,  after  adjustment  for  homeostatic  model  assessment
HOMA)  index,  the  relationship  was  no  longer  statistically
igniﬁcant,  which  implies  that  insulin  resistance  could  be
he  main  underlying  mechanism  linking  diabetes,  hyperten-
ion  and  AF  [29].  The  VALUE  trial  also  demonstrated  that
ypertension  and  diabetes  have  a  synergistic  effect  on  AF
evelopment  [30].
Movahed  et  al.  showed  that  diabetes  was  independently
ssociated  with  AF  and  atrial  ﬂutter,  as  well  as  left  ventricu-
ar  hypertrophy,  coronary  artery  disease  and  chronic  heart
ailure  [6]. Dublin  et  al.  reported  that  risk  of  AF  develop-
ent  was  higher  with  longer  duration  of  diabetes  and  worse
lycaemic  control  [23].
The  ARIC  study  showed  that  elevated  blood  pressure
as  the  most  important  contributor  to  the  burden  of  AF,
hile  merely  3%  of  AF  risk  was  explained  by  diabetes  [31].
hacker  et  al.  found  that  diabetes,  hypertension  and  blood
ressure  were  not  associated  with  permanent  AF  [32].  The
ARAF  study  also  showed  that  diabetes  did  not  contribute
o  the  progression  from  paroxysmal  to  chronic  AF  [33].  Sim-
lar  results  were  obtained  by  Tsang  et  al.  in  the  Olmstead
ounty  study  [34]. Interestingly,  the  NAVIGATOR  investiga-
ors  showed  that  impaired  glucose  tolerance  and  fasting
lasma  glucose,  but  not  progression  to  diabetes,  predict  the
isk  of  AF  [35]. On  the  other  hand,  the  results  of  the  Framing-
am  study  demonstrated  no  signiﬁcant  association  between
nsulin  resistance  and  incident  AF  [36].A  large  meta-analysis  has  shown  that  the  patients  with
iabetes  have  a  nearly  40%  greater  risk  of  AF  comparing
o  non-diabetic  patients  (relative  risk  1.39,  95%  conﬁdence
nterval  [CI]  1.10—1.75;  P  <  0.001)  [37].
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Table  1  The  effect  of  diabetes  on  AF  occurrence.
Reference  Sample  size  and  subjects  included
in  the  study
Main  ﬁndings
Movahed  et  al.
[6]
293,124  diabetic  patients  and
552,624  hypertensive  patients
Diabetes  was  a  strong,  independent
risk  factor  for  the  occurrence  of  AF
and  atrial  ﬂutter,  heart  failure,  left
ventricular  hypertrophy  and  CAD
Manitoba
Follow-Up
Study  [22]
3983  male  air  crew  recruits
observed  continuously  for  44  years;
299  developed  AF
Diabetes  was  a  signiﬁcant  risk  factor
for  AF  development
Dublin  et  al.  [23]  1410  people  with  newly  recognized
AF
Diabetes  was  associated  with  AF
occurrence;  risk  was  higher  with
longer  duration  of  treated  diabetes
and  worse  glycaemic  control
Ruigomez  et  al.
[24]
1035  conﬁrmed  incident  cases  of
chronic  AF  and  5000  controls  from
the  general  population
Diabetes  was  not  a  risk  factor  of  AF
occurrence
Danish  Diet,
Cancer,  and
Health  Study
[26]
47,589  participants  without
pre-existing  cardiovascular  or
endocrine  disease
Intermediate  occurrence  of  diabetes
during  follow-up  did  not  increase  the
risk  for  AF  development
Framingham
Heart  Study  [3]
2090  men  and  2641  women,  no
history  of  AF
Men  had  a  1.5  times  greater  risk  of
developing  AF  than  women;  diabetes
was  a  more  important  risk  factor  for
AF  in  women
Nichols  et  al.  [27]  17,372  patients  with  diabetes  and
matched  subjects  without  diabetes
Diabetes  was  an  independent
predictor  of  AF  among  women  but
not  men
Schoen  et  al.  [28]  34,720  female  health  professionals
who  were  free  of  cardiovascular
disease  and  AF  at  baseline
A  signiﬁcant  relationship  between
baseline  diabetes  and  incident  AF
could  be  mainly  explained  by  other
cardiovascular  risk  factors
Swedish
community
study  [29]
1739  subjects  of  both  genders  Diabetes  was  not  associated  with  AF,
whereas  the  combination  of
hypertension  and  diabetes  was
related  to  AF
ARIC  study  [31]  14,598  middle-aged  people
followed  for  17.1  years
Diabetes  could  explain  3%  of  the
overall  risk  for  AF  occurrence
Thacker  et  al.
[32]
1385  patients  with  newly  diagnosed
AF  whose  initial  AF  terminated
within  6  months  and  who
had  ≥  6  months  of  subsequent
follow-up
Diabetes,  blood  pressure  and
hypertension  were  not  associated
with  permanent  AF
CARAF  [33]  757  patients  with  a  baseline
diagnosis  of  paroxysmal  AF
Diabetes  did  not  contribute  to  the
progression  from  paroxysmal  to
chronic  AF
Tsang  et  al.  [34]  3248  with  paroxysmal  AF  Progression  from  paroxysmal  to
permanent  AF  was  related  to  gradual
BMI  increase,  but  not  diabetes
NAVIGATOR  study
[35]
8943  patients  without  AF  at
baseline
Impaired  glucose  tolerance,  but  not
progression  to  diabetes,  predicted
risk  of  AF
Huxley  et  al.  [37]  Meta-analysis  including  108,703
cases  of  AF  in  1,686,097  subjects
Patients  with  diabetes  had  an
approximate  40%  greater  risk  of  AF
compared  to  unaffected  patients;
the  population-attributable  fraction
of  AF  due  to  diabetes  was  2.5%
AF: atrial ﬁbrillation; CAD: coronary artery disease.
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Table  2  The  impact  of  diabetes  on  AF  recurrence.
Reference  Sample  size  and  subjects  included  in  the
study
Main  ﬁndings
Forleo  et  al.  [38]  70  patients  with  diabetes  and  paroxysmal
or  persistent  AF  treated  with  catheter
ablation
Catheter  ablation  of  AF  provides
signiﬁcant  clinical  beneﬁts  over
antiarrhythmic  drugs  in  diabetic  patients
Chao  et  al.  [13] 228  patients  with  paroxysmal  AF  who  had
undergone  catheter  ablation
Abnormal  glucose  metabolism  induced  an
intra-atrial  conduction  delay,  reduced
voltage  and  greater  recurrence  rate  after
catheter  ablation
Chang  et  al.  [39]  282  patients  with  AF  who  underwent
catheter  ablation
Metabolic  syndrome  was  associated  with
AF  recurrence  after  AF  ablation
Cai  et  al.  [40]  161  paroxysmal  AF  and  25
non-paroxysmal  AF  patients  who
underwent  catheter  ablation
Diabetes  correlated  with  AF  recurrence,
but  not  independently  of  other
cardiovascular  risk  factors
D’Ascenzo  et  al.  [41]  Meta-analysis  including  4357  patients
with  paroxysmal  AF,  1083  with  persistent
AF  and  1777  with  long-standing  AF
Diabetes  was  an  independent  predictor
of  AF  recurrence
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The inﬂuence of diabetes on recurrent AF
after catheter ablation
Catheter  ablation,  that  includes  the  isolation  of  the
pulmonary  vein,  has  been  established  as  treatment  for
drug-resistant  paroxysmal  AF.  However,  recurrence  of  AF
is  common,  and  repeated  ablation  procedures  are  still
required  in  a  signiﬁcant  percentage  of  patients  for  recurrent
AF.  The  role  of  diabetes  in  AF  recurrence  is  still  unknown,
and  the  ﬁndings  are  conﬂicting  (Table  2).
Forleo  et  al.  reported  that  catheter  ablation  of  AF  in
patients  with  diabetes  provided  signiﬁcant  clinical  bene-
ﬁts  over  the  antiarrhythmic  drugs  [38].  They  concluded  that
catheter  ablation  was  a  reasonable  approach  regarding  fea-
sibility,  effectiveness  and  low  procedural  risk.
Chao  et  al.  demonstrated  that  AF  recurrence  rate
was  greater  among  patients  with  an  abnormal  glucose
metabolism  than  in  those  without  it  (18.5%  vs  8.0%;
P  =  0.022)  [13].  The  authors  explained  these  ﬁndings  by
increased  left  atrial  size  in  diabetes  subjects,  which  could
contribute  to  the  heterogeneity  of  the  left  atrium  and  initi-
ation  of  AF.
Investigations  have  revealed  that  patients  with  metabolic
syndrome  (with  insulin  resistance  as  a  main  feature)  had  a
higher  incidence  of  recurrent  AF  compared  with  those  with-
out  metabolic  syndrome  [39].  Diabetes  was  present  in  28%  of
the  subjects  with  metabolic  syndrome.  A  higher  incidence  of
recurrent  AF  from  non-pulmonary  vein  origin  was  observed
among  patients  with  metabolic  syndrome  compared  with
those  without  (45%  vs  20%;  P  =  0.037)  [39].  Similar  results
were  recently  published  by  Cai  et  al.  [40],  who  found  that
only  metabolic  syndrome  and  obesity,  but  not  diabetes,  were
independent  predictors  of  late  AF  recurrence  (>  3  months
after  ablation).A  recent  meta-analysis  has  shown  that  valvular  AF
and  left  atrial  enlargement  (diameter  >  50  mm)  were  the
strongest  predictors  of  AF  recurrence  [41]. Diabetes,  how-
ever,  was  not  one  of  the  independent  predictors.
h
r
s
miabetes, AF and modern management
he  management  of  AF  involves  control  of  symptoms  and
revention  of  complications.  In  patients  with  diabetes,  it  is
ven  more  difﬁcult  to  achieve  these  goals.
In  the  Framingham  study,  AF  was  proven  to  be  a
rothrombotic  state  [3],  thus  anticoagulant  therapy  is  con-
idered  crucial  for  the  prevention  of  stroke;  and  guidelines
ecommend  it  for  all  AF  patients  with  at  least  one  risk  factor
or  stroke  [42].  Considering  the  fact  that  diabetes  is  a  pro-
hrombotic  state  and  one  of  the  risk  factors  of  stroke,  one
ould  conclude  that  all  patients  with  these  two  comorbidi-
ies  (diabetes  and  AF)  should  be  treated  with  anticoagulants.
art  et  al.  demonstrated  that  patients  with  paroxysmal,  per-
istent  or  permanent  AF  had  the  same  risk  of  stroke  [43],
hich  should  especially  be  kept  in  mind  in  patients  with
iabetes.
Warfarin  has  long  been  the  anticoagulant  of  choice  in
atients  with  AF.  However,  a  low  percentage  of  patients  who
each  treatment  goals  (<  40%),  need  close  monitoring,  risk
f  treatment-related  bleeding  and  interference  with  other
rugs  and  food  have  made  the  use  of  warfarin  challenging.
n  the  other  hand,  new  anticoagulants  such  as  direct  throm-
in  inhibitors  (dabigatran)  and  direct  factor  Xa  inhibitors
apixaban,  rivaroxaban,  edoxaban  and  betrixaban),  have
ppeared  on  the  market  with  much  better  pharmacokinetic
roﬁles.
Dabigatran—a  direct  thrombin  inhibitor—has  a  good
afety  proﬁle,  a  low  potential  for  drug  and  food  interac-
ions  and  does  not  interact  with  the  cytochrome  450  enzyme
ystem.  The  RE-LY  trial,  which  included  18,113  patients,
howed  that  dabigatran  administered  at  a  dose  of  150  mg,
ompared  with  warfarin,  was  associated  with  lower  rates
f  stroke  and  systemic  embolism  but  similar  rates  of  major
aemorrhage  in  patients  with  AF  and  at  least  one  additional
isk  factor,  with  a  similar  risk  of  major  bleeding  [44].  The
ame  study  demonstrated  that  diabetes  was  associated  with
ajor  bleeding  risk  in  patients  treated  with  dabigatran  [45].
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Among  direct  factor  Xa  inhibitors,  apixaban  seems  to
e  the  most  promising  and  is  approved  for  stroke  preven-
ion.  The  ROCKET  AF  trial  demonstrated  that  rivaroxaban
as  non-inferior  to  warfarin  for  the  prevention  of  stroke
r  systemic  embolism  in  patients  with  AF.  There  was
o  signiﬁcant  difference  in  the  risk  of  major  bleeding,
lthough  intracranial  and  fatal  bleedings  were  less  fre-
uent  in  the  rivaroxaban  group  [46].  The  same  trial  showed
hat  diabetes  was  not  an  independent  risk  factor  of  bleed-
ng  in  patients  with  AF  treated  with  rivaroxaban  [47].
urthermore,  a  recently  published  study  that  included
7,467  patients  treated  with  rivaroxaban  demonstrated  that
iabetes  was  not  more  prevalent  among  patients  who  expe-
ienced  major  bleeding  [48].  The  latest  analyses  of  the
RISTOTLE  study  found  that  diabetes  was  associated  with
ajor  bleeding  in  patients  with  AF  receiving  apixaban
49,50].  A  recent  meta-analysis  that  included  all  major  trials
egarding  new  anticoagulant  drugs  showed  that  these  drugs
ere  more  effective  and  safer  than  vitamin  K  antagonists
n  reducing  stroke  and  embolic  events  or  major  bleeding  in
iabetic  patients  with  AF  [51].  However,  special  attention
hould  be  directed  to  reversion  of  atrial  remodelling  in  dia-
etic  patients  with  AF.  Insulin  resistance  is  one  of  the  most
mportant  targets  in  the  management  of  these  patients.  Thi-
zolidinediones  belongs  to  a  class  of  insulin-sensitive  agents
hat  ameliorate  insulin  resistance  in  patients  with  diabetes.
Chao  et  al.  researched  the  possible  relationship  between
hiazolidinedione  treatment  and  development  of  new-onset
F  in  12,605  patients  with  diabetes  [52].  During  a  follow-
p  of  5  years,  thiazolidinediones  reduced  the  risk  of  AF
ccurrence  by  31%  after  adjustment  for  age,  underlying  dis-
ases  and  baseline  medications.  Gu  et  al.  demonstrated  that
ioglitazone  improved  the  preservation  of  sinus  rhythm  and
educed  the  re-ablation  rate  in  patients  with  diabetes  who
nderwent  catheter  ablation  due  to  AF  [53].  A  meta-analysis
f  19  randomized  clinical  studies  showed  that  pioglitazone
as  associated  with  a  signiﬁcantly  lower  risk  of  death,
yocardial  infarction  and  stroke  among  patients  with  dia-
etes  [54].
Probucol,  a  lipid-lowering  drug  with  a  potent  antioxi-
ant  effect,  could  positively  inﬂuence  atrial  remodelling  in
F  [55].  Speciﬁcally,  this  agent  may  reduce  the  production
f  oxygen  free  radicals,  increase  the  expression  of  antioxi-
ant  enzymes,  such  as  glutathione  peroxidase,  prevent  lipid
eroxidation,  and  inhibit  the  activity  of  nicotinamide  ade-
ine  dinucleotide  phosphate-oxidase.  Gong  et  al.  reported
hat  probucol  reduced  C-reactive  protein  concentration  and
ttenuated  atrial  oxidative  stress,  signiﬁcantly  decreased
trial  heterogeneous  sympathetic  hyper-innervation,  and
adically  reduced  the  inducibility  and  duration  of  AF  [56].
Current  data  show  that  angiotensin-converting  enzyme
ACE)  inhibitors  and  angiotensin  II  receptor  blockers  (ARBs)
ould  prevent  the  development  of  AF.  This  could  be  due
o  the  up-regulation  of  the  RAAS  that  is  seen  in  diabetes,
nd  which  represents  a  key  mechanism  in  the  pathogene-
is  of  AF.  A  meta-analysis  of  26  randomized  clinical  trials
stimating  the  effect  of  ACE  inhibitors  or  ARBs  on  the  pre-
ention  of  AF  showed  that  both  drugs  had  preventive  effects
n  AF  (odds  ratio  0.65,  95%  CI  0.55—0.76)  and  these  effects
ere  similar  in  these  two  classes  of  drugs  [57].  However,
CE  inhibitors  and  ARBs  showed  higher  beneﬁt  effects  on
ecurrent  AF  than  on  new-onset  AF.  A  subgroup  analysis  ofM.  Tadic,  C.  Cuspidi
atients  with  risk  factors  for  AF  (hypertension,  diabetes,
oronary  artery  disease  and  heart  failure)  revealed  that  the
se  of  ACE  inhibitors  or  ARBs  could  not  prevent  recurrence
f  AF  after  catheter  ablation  [58].  On  the  other  hand,  Fogari
t  al.  showed  that  valsartan  was  effective,  even  more  than
tenolol,  in  preventing  recurrent  paroxysmal  AF  (20.3%  vs
4.1%)  in  296  patients  with  hypertension  and  diabetes  [59].
Some  non-antiarrhythmic  drugs  directed  against  atrial
tructural  and  electrical  remodelling,  inﬂammation  and
xidative  stress  have  been  suggested  as  novel  therapeutic
pproaches  in  the  management  of  AF.  This  group  of  agents
ncludes  statins,  n-3  polyunsaturated  fatty  acids  and  several
ntioxidant  drugs  such  as  vitamins  C  and  E,  N-acetylcysteine
nd  xanthine  oxidase  inhibitors  [60—62]. However,  we  still
eed  prospective  studies  to  conﬁrm  the  protective  effect  of
hese  agents  on  AF  occurrence  in  patients  with  diabetes.
onclusions
F  is  commonly  present  in  patients  with  diabetes,  and  these
wo  conditions  will  be  seen  together  more  frequently  in  the
uture  because  the  prevalence  of  both  is  increasing.  Thus,  it
s  very  important  to  establish  the  most  effective  treatment
n  this  subpopulation  of  patients  with  AF.  New  prospective
tudies  with  large  numbers  of  patients  with  diabetes  and
F  are  needed  to  investigate  the  mechanisms  of  this  rela-
ionship  and  all  possible  therapeutic  approaches  in  order  to
etermine  the  best  possible  individual  management  of  both
onditions.
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